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sciences. China is a late starter in the development of translational medicine, yet the Chinese
medical community has already demonstrated its determination towards the realisation of this
concept. There are many questions that need to be answered prior to when translational med-
icine can proceed from being a concept to reality. This paper highlights the essential require-
ments for developing “patients and clinic oriented” translational medicine and shares “an
enriched stem cells technique” as an example of orthopaedic translation. Enormous collabora-
tive and multidisciplinary work is required prior to when the results of scientific research can
be translated into effective clinical practice.
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“There was a widening gap between basic and clinical
research”. “The clinical and basic scientists don’t really
communicate”. These are the descriptions of the relation-
ship between basic research and clinical practice by Elias
Zerhouni and Barbara Alving from the National Institutes of
Health (NIH) of the United States [1,2]. Actually, this gapslational Center of Stem Cell
ple’s Hospital, Shanghai Jiao
hanghai, China.
.-R. Dai).
.07.003
hors. Published by Elsevier (Singa
licenses/by-nc-nd/4.0/).has already appeared during the rapid development of life
sciences in the 20th century. In 101 papers published in
Science, Nature, Cell, and other leading journals from 1979
to 1983, only five papers obtained approval for clinical
application 20 years later, and only one paper showed a
prominent impact on clinical practice. However, all these
papers had stated that they would have significant value for
clinical application [3]. It was pointed out by Professor
Philip Greenland of the Northwest University that the mean
time from the start of the development of a new drug until
it eventually gains Food and Drug Administration approval
was 14 years. Therefore, considerable efforts have been
made to shorten the process from basic research to clinical
application, and thus to promote the use of new drugs, newpore) Pte Ltd. This is an open access article under the CC BY-NC-ND
Figure 1 Traditional research pattern.
Translational medicine in China 7technologies, and new therapies for servicing our patients,
which is also the initial intention of “translational
medicine”.
In the United States, it took 8 years from the time “The
NIH Roadmap” project was proposed in 2003 until the
establishment of 60 clinical translational centres (2011).
However, the development of translational medicine in
China has been much faster. In just 4 years (from 2009 to
2012), more than 50 translational medicine institutions
have been established in China, covering stem cells, re-
generative medicine, drug development, cancer, musculo-
skeletal system, leukaemia, cardiovascular, paediatrics,
diabetes, etc. Academic conferences on translational
medicine have been held in various cities. In the National
Twelfth Five-Year Plan for the Science and Technology
Development, the Chinese government also stated that “we
are going to improve the level of medical sciences and
strengthen the construction of key medical disciplines
centred by translational medicine”, indicating that trans-
lational medicine has been regarded as a major strategy in
the medical field of China. Although the establishment of
translational medical platforms spread the concepts of
translational medicine and met the requirement of the
development of medicine in China, many issues have also
cropped up during the process. For example, there are
various opinions about translational medicine, but this only
resulted in limited connections between laboratories and
clinics, with no concrete results in practice. In addition,
there is a lack of clarity in terms of the responsibility, work
protocols, personnel, and evaluation systems for trans-
lational medicine projects. How translational medicine
differs from conventional medical research remains an
open question. Thus, it was asked: “What is the essential
nature of translational medicine that distinguishes it from
the conventional medical research? Isn’t what we have
been doing just translational medicine? What is new about
the translational medicine?”
It is true from a certain perspective that we and our
medical pioneers have always been advocating and prac-
tising translational medicine. The legend of “Shennong
Tastes a Hundred Grasses” is a good example, in that Shen-
nong translated the knowledge of herbs into medications for
the treatment of diseases. It can be said that the concept of
translational medicine has been implemented from the very
beginning of the development ofmedicine, but our ancestors
just conducted their medical research and medical practice
within the same group of like-minded individuals. The gap
between basic research and clinical practice or health stra-
tegies widened as the medical sciences became more spe-
cialised. The translation between basic research and clinical
application is no longer as simple and direct as it was in the
past. Translational research is a grand “feast” in themedical
field, so it is worthwhile to spend time on reflecting and
exploring how to share the feast with everyone. Throughout
those years, the practice of translational medicine in China
has been focussing on “innovation”, such as the research on
pathological mechanisms, treatment targets, and drug de-
velopment. However, our international peers, especially
those in the United States, also focused their efforts to
translate current theories and technologies into effective
clinical treatments, especially emphasising on the interme-
diate process of translation, so as to promote cooperationbetween research teams and manufacturing enterprises,
increasing investments in clinical trials, and optimising the
approval process. Therefore, it is suggested that at least the
following four aspects should be adjusted for the develop-
ment of translational medicine in China.Four aspects to be adjusted for the development of
translational medicine
Aspect no. 1: adjustment of the research mode
Conventional medical research has the following trend:
basic research / research findings / determine trans-
lational targets / patent application and approval /
design and implementation of clinical trials and industriali-
sation / clinical application / find out issues / basic
research. However, basic research usually did not go further
after the publication of findings. Only a small part of the
findings of basic research was considered relevant for clin-
ical application(s). This approach is random in nature, and
the researchers probably give up halfway through because of
the time-consuming process required (Fig. 1). Even if they
had persisted in their efforts, the efficiency of translation is
very low because newer research projects greatly affected
their progress, and may even have finally prompted them to
abort their plans. This research mode is passive with a low
probability and motivation towards clinical translation,
because for this kind of research, the researchers are usually
in the lead position and the major criterion for their per-
formance evaluation is publicationdand not clinical trans-
lation. We analysed the regenerative medicine-related
patents applied from 2005 to 2009 by the Departments of
Stomatology, Plastic Surgery, and Orthopaedics of the Ninth
People’s Hospital, Shanghai Jiao Tong University School of
Medicine. The results showed that 52% of the patents were
not translated by 2011, only 3% have nearly finished the
translation process (utilising the clinical application of pat-
ents as the completion of translation), 12% were being pro-
cessed, and 33%were in the planning stage. Evenwhen taken
together with the patents of clinical techniques, only 7% of
the patents went through the translation process. There-
fore, we propose a novel research model: clinical issues and
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research findings/ clinical trial/ clinical application/
find new issues/ new round of basic research. In this mode,
all the components are guided by clinical requirements, such
as policy and financial support, multi-discipline coopera-
tion, and talent cultivation. With definite targets for clinical
application, the translational process can start in the design
phase of the research, which is very attractive for enter-
prises. Therefore, this demand-driven mode directly aims at
clinical issues with a clear approach, motivation, and high
efficiency (Fig. 2). This scheme has already been imple-
mented in the Clinical Translational Center of Stem Cell and
Regenerative Medicine, where the authors are working. By
reviewing the applied patents and the current research,
those findings that may contribute to solving clinical issues
are identified and then listed into translational projects,
which significantly promotes the translational process.
Aspect no. 2: adjustment of the research objects
Medical research is far more complex and demanding than
the research conducted in other disciplines, because per-
fect replication of human physiology and pathology in ani-
mals is virtually impossible. However, the explosive growth
of scientific findings in medical research in the past decades
failed to bring qualitative improvement to human health.
For example, hundreds of billions of dollars’ worth of in-
vestment in cancer research in the United States did not
significantly reduce cancer-related mortality. Conventional
medical research consumed a huge amount of resources
and labour in cell and animal experiments, and it was
shown that the research subjects in 80% of tumour-related
papers were mice, fruit flies, and Caenorhabditis elegans,
which inspired the joke that medical research is basically
animal research. Although this saying is biased, the
importance of basic research to the development of med-
ical sciences should not be neglected. Without high-quality
basic research findings, translational medicine would be
rootless. However, we should go beyond the findings from
in vitro and in vivo experiments, and translate these find-
ings into practical techniques, new drugs and instruments,
as well as health policies for the service of human health.
Therefore, the focus on being “patients and clinic ori-
ented” is the essential difference between translational
medicine and basic research, and is also the most difficultFigure 2 Demand-driven research.transition for conventional concepts and practices. Trans-
lational medicine is not intended to replace or compromise
basic research. During the entire process of basic research,
the concept of translational medicine should be kept in
mind. It is well known that research funding is preferen-
tially invested in animal experiments, cell technologies,
and molecular biology because of the rapid and potentially
lucrative payback. By contrast, in the aspect of clinical
translation, it is risky; a substantial amount of research
findings are being forgotten; the funding that is put into
translational and clinical studies is limited; clinical trans-
lation lacks guidance and support from the government.
The reasons for these are encapsulated in the following
facts. (1) Clinical studies are capital-intensive, and realis-
ing that industrialisation may cost tens of millions or even
billions of dollars. However, only a small amount of
research funds or investment could be obtained and is
usually not enough to support such expensive clinical
studies. (2) Clinical studies require the involvement of
many institutions with good coordination, and they are
time- and labour-intensive ventures. (3) The input and
output of clinical study are not cost-effective, which
cannot comply with current evaluation systems. The
amount of publications is the major evaluation criterion for
many individuals and research institutions, so achievements
in translational research have received little priority. (4)
Clinical studies are faced with greater risks and more strict
ethical and regulatory constraints. (5) Clinical studies have
to face the difficulties and challenges brought by industri-
alisation. So in order to establish a good translational
medicine platform, these barriers must first be overcome.
An optimal setup must ensure that the funds are used for
clinical translation, and financial support must be available
to accommodate the patients who are participating in
clinical validation studies with informed consent. Only in
this way can we formulate effective clinical technology,
drugs, medical instruments, and strategies for epidemic
prevention. It should be emphasised that this not only
guarantees the translational process, but also provides free
and advanced medical services to patients. Certainly, pa-
tients and doctors have to face the risks brought about by
translational medicine.
Aspect no. 3: adjustment of the roles of the institution
The National Center for Research Resources of the NIH
defined its mission in the translational research as providing
any necessary support(s) to promote the translation from
basic research findings to practices that benefit human
health. In other words, the mission of a translational
research centre or platform is to provide services and pro-
mote clinical translation. It should provide those conditions
that originally do not have, in terms of software and hard-
ware, systemmanagement, data processing, and education/
training, and integrate professionals in statistics, epi-
demiology, ethics, laws, regulation, and patent application.
When necessary, it should help to establish relevant facilities
such as biobanks, cell banks, large animal centres, and GMP
(GoodManufacture Practice) cleaning rooms. Two functional
structures are essential for a translational medicine centre/
platform: the institutional review board (IRB) and the
administration office. The IRB is in charge of reviewing,
revising, and approving the projects that are qualified for the
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uation of the ongoing translational projects. The other key
structure to ensure the normal operation of translational
centre is the administration office with the function of ser-
vice management, that is to say, the mission of an adminis-
tration office is to provide services, including providing
support and info-services for the IRB, dynamic info-exchange
and info-structure for the translational projects, optimisa-
tion for the management of talent and material resources in
the process of implementing the plan, construction, and
maintenance of the websites (intranet and internet),
establishment of the materials and survey research centre,
and providing help in terms of technical support, talent
training, clinical trial, certificate application, GMP cleaning
room, and initialising industrialisation, etc. In the first ple-
nary conference of our translational centre, two aspects
were emphasised: (1) it is clearly stated that the intellectual
properties, awarding, and commercial interests involved in
translational research are exclusive to the project team; and
(2) confidential terms were signed by the researchers as well
as the IRB members to protect the interests of research
teams. Moreover, personnel selection should be highly
valued, because personnel are the principal basis for the
initialisation, construction, and development of the trans-
lational centre.
Aspect no. 4: adjustment of the evaluation criteria
In a conventional research institution, project approval
and evaluation focus on academic innovation and break-
through, and although clinical significance is mentioned, it
is not necessarily the main priority. By contrast, trans-
lational research should target clinical application and
patient benefits, whereas publication is not a priority;
thus, the evaluation criteria should also be adjusted. The
evaluation of a translational project covers three phases.
(1) Access evaluation. A feasibility study is performed for
each candidate project. Safety is the basic requirement. A
project must also prove that: it has a definite object and
scientific value; it will comply with ethical and statistical
requirements; difficult and condition evaluations all have
to be analysed. If necessary, peer review can also be
conducted. (2) Process evaluation is periodically per-
formed to monitor the progress of the project, scientific
and technological issues, management, talent training,
clinical trial, certificate application, industrialisation,
community cooperation, multi-discipline and international
cooperation, and funding usage, etc. (3) Outcome evalua-
tion focuses on whether the expected objectives are ach-
ieved, whether the patients received benefits, and the
possibility of further study. In addition, periodical SWOT
analysis (strength, weakness, opportunities, and threats) is
recommended for both the project team and the trans-
lational centre.
The concept changing makes the practice of translational
medicine no longer just a formality, and also renders it
different from conventional medical research. However, it is
still challenging to make concrete measures and establish an
effective operation mode for translational medicine. Or-
thopaedic research involves multiple disciplines such as
material sciences, engineering, and biomechanics, and has
always been a representative for the concept of “trans-
lational medicine”. Novel technologies in biomaterials,manufacturing, and imaging are emerging continuously, and
orthopaedic researchers are facing the challenges and/or
have the mission to translate basic research findings into
effective clinical management. The authors of this pers-
pective paper have been performing translational research
targeting bone defects and nonunion, and hope to establish a
model for orthopaedic translational medicine.Enrichment technique of stem cells as a model
for orthopaedic translational medicine
Since the early 1990s, stem cell technology has developed
rapidly and researchers have started to realise that stem
cell technology has the potential to solve many tricky
clinical problems in the next 50 years, including Parkinson’s
disease, diabetes, myocardial infarction, and bone and
cartilage injuries. Thus, our Orthopaedic Department in-
troduced stem cell research into our orthopaedic research
programme. At that time, bone marrow-derived mesen-
chymal stem cells (MSCs) were considered to have the most
promising potential for clinical translation. Our procedures
for stem cell therapy included the following steps: firstly,
5e10 mL bone marrow is harvested from donors, followed
with culture and amplification of MSCs in vitro; up to
106e107 MSCs obtained within a few weeks. And then,
through induction and differentiation, osteoblast or chon-
droblast cells were used in injection or tissue engineering
approach for repairing bone or cartilage defects. In addi-
tion, a variety of cytokines were tested, such as BMP-2, to
promote osteogenic differentiation. Transgenic techniques
were also developed, for example, the adenovirus nuclear
transfection technology, which integrated the target genes
with the DNA of stem cells to obtain a long-lasting expres-
sion of osteogenic or chondrogenic cytokines, thus pro-
moting the differentiation of stem cells to repair the bone
or cartilage defects [4e6]. Meanwhile, the development of
bony conductive materials also shows the potential to
accelerate bone repair, such as calcium phosphate ce-
ramics, and chitosan. However, when it comes to clinical
use, a number of problems ensued.
It is not only the translation of transgenic technology
into clinical practice that needs to meet strict criteriad-
even translating the most common technique of in vitro cell
amplification is required to comply with current good lab-
oratory practices and the current GMPs, as well as to obtain
the authorisation of investigational new drug application or
investigational device exemption from the Chinese State
Food and Drug Administration. The whole process is time-
consuming; it also requires huge investments with full
personnel and equipment support, which is not cost-
effective. Moreover, the long period of cell culture, the
risk of contamination, and the application of animal serum
in the culture medium could stir ethical controversies and
restrictions; therefore, it is difficult to promote stem cell
technology in clinics in the short term.
We therefore tried to overcome the above obstacles from
clinical requirements and started the research on the con-
centration technique of bone marrow mononuclear cells
since the year 2000 to look for solutions for our stem
cell programme. Based on the basic scientific studies, we
improved the technique and created the enrichment
Figure 3 The stem cell screen-enrich-combined circulating
system.
10 K.-R. Dai et al.technique of bone marrow stromal cells (BMSCs), in combi-
nation with new degradable porous biomaterials to promote
bone repair. Animal experiments showed that this technique
could rapidly enrich BMSCs, without affecting cell prolifera-
tion or increasing the ratio of cell apoptosis, mechanical
injury, and necrosis. By combining with porous tri-calcium
phosphates, enriched BMSCs had better activities of prolifer-
ation, metabolism, and osteogenesis, which could promote
goat posterior spinal fusion. After a series of in vivo and
in vitro experiments, we finally applied this regenerative
medicine technology in our orthopaedic clinicdthat is, we
used it to perform the surgery peri-operatively, without per-
forming cell culture in vitro, nor requiring twice the amountof
anaesthesiausedandoperation, norwaiting for 3weeksofcell
culture. When the preparation of bone graft sites is
completed, the enriched MSCs/biomaterials could be imme-
diately implanted in vivo [7]. Therefore, it evades the issues
brought on by in vitro cell culture. To date, more than 100
patients who needed spinal fusion or suffered non-union
fracture have benefited from this technique, and 91% of
cases had good results [7]. Furthermore, this technique has
been adopted by some plastic surgeons for the growth of
expanded skin flap.
Although the enrichment technique of BMSCs cannot
replace the technique of in vitro cell culture, it appears to
be simpler, more directed, and easier for clinical trans-
lations. However, the expensive cell processor became the
biggest obstacle for the promotion of its clinical applica-
tion; thus, there was an urgent need to improve the
apparatus and technique, as well as reduce the cost.
In clinical studies, we found the rapid adhesive properties
of bone marrow MSCs. After the filtrating process (which
lasted several minutes), the MSCs, which account for a small
number of bone marrow, could be substantially retained in
the plastic filter screen, even though the diameter of the
screen mesh is much larger than that of the cells. Thus, we
began to focus our research on the BMSC rapid filtratinge-
screeningeenriching technique. We changed the filter
screen into biodegradable porous materials for bone repair,
combining BMSC screening, enriching and compositing ma-
terials together, which not only simplified the procedure and
accelerated itsmanufacture, but also decreased the times of
cell transfer as well as enhanced security and efficiency.
Following the research, we began to develop a disposable
screen devicedthe stem cell screen-enrich-combined
circulating system (Fig. 3). Compared with the cost of a
typical blood cell processor ($6000), it is considerably less
expensive as well as being simpler, safer, easier to use for
clinical applications, and is a disposable device. Cooperative
agreement about this technique has been signed with rela-
tive enterprise. The design and production of the new device
have also been completed and have received approval. A
clinical trial is about to start.
From the basic scientific study of cytological culture, to
the study of enrichment technique of stem cells, to the
development of filtratingescreeningeenriching technique,
and finally to the innovation and clinical verification of
stem cell screen-enrich-combined circulating system, we
adopted a good translation medicine model from basic
research to clinical applications, and relevant innovations
acquired seven patents from our innovative translational
research programmes.Conclusion
We urge that further reflection and exploration on how to
bring translational medicine from a simple concept to
actual practice be undertaken. This paper elaborated our
experience in the field of translational medicine in terms of
concept-changing and case study, which we hope will pro-
vide inspiration to other translational researchers.References
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